The Effect of Renin Inhibition on Nerve Function in Diabetes



Status:Completed
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2009
End Date:April 2012

Use our guide to learn which trials are right for you!

Effect of Renin Inhibition on Cardiovascular Autonomic Nerve Function in Diabetes

This study will assess the effect of direct renin inhibition on nerve function in persons
with diabetes using a double-blind, placebo-controlled randomized trial involving two
treatment arms (i.e., [1] 30 participants enrolled and randomized to 300 mg of Aliskiren;
[2] 30 participants enrolled and randomized to placebo).


Inclusion Criteria:

- Individuals >18 years old with type 1 or type 2 diabetes mellitus.

Exclusion Criteria:

- Individuals currently taking the maximum dose of an ACE inhibitor or an ARB.

- Individuals with a history of a MI, percutaneous coronary interventions, coronary
artery bypass graft (CABG) surgery, acute coronary syndromes, recent/on going atrial
fibrillation, frequent atrial arrhythmias, frequent ventricular arrhythmias, or acute
myocardial ischemia changes.

- Individuals whose treatment dosage changes 2 months prior to the study for
antihypertensive and antidiabetes medications, and the following medications that may
affect the ANS: anti-tuberculosis drugs, nitrofurantoin, metronidazole,
chloramphenicol, perhexiline maleate, amiodarone, clofibrate, tricyclic
antidepressants, phenytoin, barbiturates, neuroleptic, antiparkinsonism drugs, and
nitrated drugs.

- Pregnant or lactating females.

- Individuals with impaired renal function (i.e., creatinine >1.5 mg/dl), a history of
dialysis, nephritic syndrome or renovascular hypertension.

- Individuals with potassium levels within 0.5 mmol/L of the upper limit of normal
(i.e., hyperkalemia).
We found this trial at
1
site
Newark, Delaware 19713
?
mi
from
Newark, DE
Click here to add this to my saved trials